New AI tool predicts whether aggressive small cell lung cancer will respond to treatment

Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...
Seeking Alpha

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the ...
Business Wire

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology ...

Genomic Profiling with MammaPrint® + BluePrint® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer

Study of over 1000 females with breast cancer finds that genomic risk and molecular subtype, and not race, drives ...

Agendia, Inc.: Genomic Profiling with MammaPrint + BluePrint Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2- Early-Stage Breast Cancer

Multicenter study of over 1000 females with breast cancer, published in npj Breast Cancer, finds that genomic risk and molecular subtype, and not race, drives differential survival outcomes Agendia ...